Search Within

Tala Shekarkhand

Formats
  1. Meeting Abstract (34)
  2. Journal Article (8)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Hematologic Malignancies, Division of (45)
  2. Center for Hematologic Malignancies (44)
  3. Department of Medicine (44)
  4. Hematologic Malignancies Research (44)
  5. Myeloma (44)
  6. CTCR Scholars (42)

More Groups

People
  1. Alexander Lesokhin (44)
  2. Carlyn Rose Tan (42)
  3. Hani Hassoun (42)
  4. Malin Hultcrantz (42)
  5. Sham Mailankody (42)
  6. Urvi Shah (42)

More People

Years
  1. 2025 (3)
  2. 2024 (22)
  3. 2023 (13)
  4. 2022 (3)
  5. 2021 (1)
  6. 2020 (2)

More Years

Publications
  1. Blood (21)
  2. Clinical Lymphoma, Myeloma and Leukemia (12)
  3. Blood Advances (4)
  4. Blood Cancer Journal (2)
  5. Journal of Clinical Oncology (2)
  6. Blood Neoplasia (1)

More Publications

Publishers
  1. American Society of Hematology (25)
  2. Elsevier Inc. (13)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (45)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Whole genome sequencing reveals lower APOBEC-mutational activity in multiple myeloma patients with African ancestry compared with those having European ancestry
    Meeting Abstract

    Maclachlan, K. H.; Papadimitriou, M.; Blaney, P.; Shekarkhand, T.; Chu, T. R.; Poos, A. M.; Brown, E.; Hoering, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save